Effectiveness and Safety of Dabigatran, Rivaroxaban, and Apixaban Versus Warfarin in Nonvalvular Atrial Fibrillation

2016414 citationsJournal Articlegold Open Access

Authors

Xiaoxi Yao · Mayo Clinic in Florida

Neena S. Abraham · Mayo Clinic in Florida

Lindsey R. Sangaralingham · Mayo Clinic in Arizona

Fernanda Bellolio · Mayo Clinic in Arizona

Robert D. McBane · Mayo Clinic in Arizona

Nilay D. Shah · Optum (United States)

Peter A. Noseworthy ·

Abstract

In patients with nonvalvular atrial fibrillation, apixaban was associated with lower risks of both stroke and major bleeding, dabigatran was associated with similar risk of stroke but lower risk of major bleeding, and rivaroxaban was associated with similar risks of both stroke and major bleeding in comparison to warfarin.

Topics & Keywords

Atrial Fibrillation Management and Outcomes Cardiac Arrhythmias and Treatments Venous Thromboembolism Diagnosis and Management

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Journal of the American Heart Association

Volume 5, Issue 6

DOI: 10.1161/jaha.116.003725

Field-Weighted Citation Impact: 50.90